(R)N-[3-(5-chloro-2-methoxyphenyl)-1-(2-hydroxy-3-(pyrrolidin-1-yl)propyl)-1H-pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide | 1260164-36-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (R)N-[3-(5-chloro-2-methoxyphenyl)-1-(2-hydroxy-3-(pyrrolidin-1-yl)propyl)-1H-pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
• 英文别名: N-[3-(5-chloro-2-methoxyphenyl)-1-[(2R)-2-hydroxy-3-pyrrolidin-1-ylpropyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
• CAS: 1260164-36-0
• 化学式: C₂₄H₂₆ClN₇O₃
• 分子量: 495.969
• InChiKey: NJBGFUHKCTXEBO-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Gibbons Paul

  公开号：US20120190665A1

  公开（公告）日：2012-07-26

  A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

  公式I的化合物、对映异构体、顺反异构体、互变异构体或其药学上可接受的盐，其中R1、R2和R3的定义如本文所述，可用作一种或多种Janus激酶的抑制剂。本文还揭示了一种包括公式I的化合物和药学上可接受的载体、辅料或载体的药物组合物，以及治疗或减轻患者对Janus激酶活性抑制响应的疾病或状况的方法。
• US8999998B2
  申请人：——

  公开号：US8999998B2

  公开（公告）日：2015-04-07
• [EN] PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS PYRAZOLOPYRIMIDINE INHIBITEURS DES JAK ET PROCÉDÉS
  申请人：GENENTECH INC

  公开号：WO2011003065A2

  公开（公告）日：2011-01-06

  A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.